216 related articles for article (PubMed ID: 35084934)
1. Disease Modification in Myelofibrosis: An Elusive Goal?
Vachhani P; Verstovsek S; Bose P
J Clin Oncol; 2022 Apr; 40(11):1147-1154. PubMed ID: 35084934
[No Abstract] [Full Text] [Related]
2. Are we altering the natural history of primary myelofibrosis?
Savona MR
Leuk Res; 2014 Sep; 38(9):1004-12. PubMed ID: 24931396
[TBL] [Abstract][Full Text] [Related]
3. [Molecular pathology and treatment for primary myelofibrosis].
Kitanaka A; Shimoda K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():321-5. PubMed ID: 23133975
[No Abstract] [Full Text] [Related]
4. When to initiate treatment in myelofibrosis.
Harrison C
Clin Adv Hematol Oncol; 2016 Nov; 14(11):934-937. PubMed ID: 27930645
[No Abstract] [Full Text] [Related]
5. [Pathophysiology of and therapy for primary myelofibrosis].
Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1724-32. PubMed ID: 17802728
[No Abstract] [Full Text] [Related]
6. Myelofibrosis: to transplant or not to transplant?
Devlin R; Gupta V
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):543-551. PubMed ID: 27913527
[TBL] [Abstract][Full Text] [Related]
7. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia.
Fiorini A; Reddiconto G; Farina G; Marietti S; Palladino M; Chiusolo P; Leone G; Sica S
Leukemia; 2006 Dec; 20(12):2198-9. PubMed ID: 17039230
[No Abstract] [Full Text] [Related]
8. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N; Alchalby H; Klyuchnikov E; Badbaran A; Hildebrandt Y; Ayuk F; Bacher U; Bock O; Kvasnicka M; Fehse B; Zander A
Blood; 2009 Feb; 113(8):1866-8. PubMed ID: 19228938
[No Abstract] [Full Text] [Related]
9. Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.
Shah MV; Patel KP; Luthra R; Kanagal-Shamanna R; Mehrotra M; Bachegowda LS; Champlin RE; Verstovsek S; Popat UR
Br J Haematol; 2018 Dec; 183(5):831-835. PubMed ID: 29265180
[No Abstract] [Full Text] [Related]
10. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
11. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
Barba P; Fox ML; Blanco A; Valcárcel D
Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
[No Abstract] [Full Text] [Related]
12. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
Shanavas M; Gupta V
Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation for myelofibrosis in 2012.
McLornan DP; Mead AJ; Jackson G; Harrison CN
Br J Haematol; 2012 May; 157(4):413-25. PubMed ID: 22463701
[TBL] [Abstract][Full Text] [Related]
14. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
15. [Myelofibrosis in a new light. New classification introduced, new therapeutic principles on their way].
Merup M; Palmblad J
Lakartidningen; 2009 Dec 2-8; 106(49):3342, 3344-6. PubMed ID: 20104733
[No Abstract] [Full Text] [Related]
16. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation.
Benjamini O; Koren-Michowitz M; Amariglio N; Kroger N; Nagler A; Shimoni A
Leukemia; 2008 Oct; 22(10):1961-3. PubMed ID: 18685610
[No Abstract] [Full Text] [Related]
17. Autologous reconstitution leading to sustained JAK2-V617F negativity post allogeneic hematopoietic stem cell transplant in JAK2-V617F positive myelofibrosis.
Torka P; Hahn T; Bertolo J; Liu H; Ross M; Paplham P; Jankowski A; Deeb G; Chen G; McCarthy P
Bone Marrow Transplant; 2015 Nov; 50(11):1480-2. PubMed ID: 26214139
[No Abstract] [Full Text] [Related]
18. Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
Viswabandya A; Devlin R; Gupta V
Curr Hematol Malig Rep; 2016 Feb; 11(1):6-11. PubMed ID: 26659587
[TBL] [Abstract][Full Text] [Related]
19. Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.
Kosiorek HE; Scherber RM; Geyer HL; Verstovsek S; Langlais BT; Mazza GL; Gotlib J; Gupta V; Padrnos LJ; Palmer JM; Fleischman A; Mesa RA; Dueck AC
Br J Haematol; 2022 Sep; 198(6):1065-1068. PubMed ID: 35751150
[No Abstract] [Full Text] [Related]
20. New strategies in myelofibrosis: the evolving paradigm of disease pathogenesis, prognostication and treatment.
Palandri F; Auteri G; Baccarani M
Hematol Oncol; 2017 Jun; 35(2):145-150. PubMed ID: 27510853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
